Shire
Business & Industry
- AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
- Bayer Foundation announces Science Awards winners of 2024
- GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
- Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
- U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
Research & Development
- New hope for diabetic heart disease treatment
- First molecule identified that promotes gut healing while inhibiting tumour progression
- Stopping severe malaria by harnessing natural human antibodies
- Technion researchers have developed a new chemical process: Triazenolysis
- New drug targets for Alzheimer's identified from cerebrospinal fluid
- New weight loss drug target burns energy and lowers appetite - without the nausea and vomiting
- How immune cells "sniff out" pathogens
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy